nodes	percent_of_prediction	percent_of_DWPC	metapath
Moxifloxacin—TOP2A—Valrubicin—urinary bladder cancer	0.602	0.741	CbGbCtD
Moxifloxacin—TOP2A—Epirubicin—urinary bladder cancer	0.0912	0.112	CbGbCtD
Moxifloxacin—TOP2A—Etoposide—urinary bladder cancer	0.0711	0.0874	CbGbCtD
Moxifloxacin—TOP2A—Doxorubicin—urinary bladder cancer	0.0485	0.0596	CbGbCtD
Moxifloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—urinary bladder cancer	0.00146	0.097	CbGpPWpGaD
Moxifloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—urinary bladder cancer	0.000887	0.0588	CbGpPWpGaD
Moxifloxacin—TOP2A—G0 and Early G1—CCNE1—urinary bladder cancer	0.00074	0.049	CbGpPWpGaD
Moxifloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—urinary bladder cancer	0.000697	0.0462	CbGpPWpGaD
Moxifloxacin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000543	0.125	CbGdCrCtD
Moxifloxacin—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000543	0.125	CbGdCrCtD
Moxifloxacin—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000543	0.125	CbGdCrCtD
Moxifloxacin—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000543	0.125	CbGdCrCtD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	0.000463	0.0306	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000426	0.0282	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	0.000394	0.0261	CbGpPWpGaD
Moxifloxacin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000363	0.0835	CbGdCrCtD
Moxifloxacin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000363	0.0835	CbGdCrCtD
Moxifloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	0.000343	0.0227	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—SMC1B—urinary bladder cancer	0.000334	0.0221	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—RRM2—urinary bladder cancer	0.000326	0.0216	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.0003	0.0198	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	0.000273	0.0181	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	0.000268	0.0177	CbGpPWpGaD
Moxifloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	0.000261	0.0173	CbGpPWpGaD
Moxifloxacin—TOP2A—Gastric Cancer Network 2—MYC—urinary bladder cancer	0.000247	0.0164	CbGpPWpGaD
Moxifloxacin—TOP2A—Gastric Cancer Network 2—EGFR—urinary bladder cancer	0.000242	0.016	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000229	0.0151	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000227	0.015	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	0.000209	0.0138	CbGpPWpGaD
Moxifloxacin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	0.000204	0.047	CbGdCrCtD
Moxifloxacin—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	0.000203	0.0134	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	0.000192	0.0127	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	0.000191	0.0127	CbGpPWpGaD
Moxifloxacin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000189	0.0436	CbGdCrCtD
Moxifloxacin—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000189	0.0436	CbGdCrCtD
Moxifloxacin—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	0.000189	0.0436	CbGdCrCtD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	0.000189	0.0125	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000183	0.0121	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	0.000182	0.012	CbGpPWpGaD
Moxifloxacin—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000175	0.0403	CbGdCrCtD
Moxifloxacin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000175	0.0403	CbGdCrCtD
Moxifloxacin—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000175	0.0403	CbGdCrCtD
Moxifloxacin—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	0.000171	0.0113	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	0.000147	0.00973	CbGpPWpGaD
Moxifloxacin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	0.000146	0.0337	CbGdCrCtD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000145	0.00963	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	0.000145	0.0096	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	0.000145	0.0096	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000143	0.00946	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000137	0.00908	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000136	0.00897	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	0.000135	0.00893	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	0.00013	0.00864	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	0.00013	0.00859	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	0.00013	0.00859	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	0.000128	0.00846	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000127	0.00838	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	0.000121	0.00804	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	0.000119	0.00791	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	0.000112	0.00744	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000112	0.0074	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000111	0.00737	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000111	0.00734	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	0.000108	0.00716	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000107	0.00708	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	0.000107	0.00707	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	0.000102	0.00672	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	9.72e-05	0.00643	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	9.71e-05	0.00643	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	9.6e-05	0.00635	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	9.49e-05	0.00628	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	9.18e-05	0.00608	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	9.08e-05	0.00601	CbGpPWpGaD
Moxifloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	8.89e-05	0.00588	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	8.14e-05	0.00539	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	7.96e-05	0.00527	CbGpPWpGaD
Moxifloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	7.61e-05	0.00504	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	7.19e-05	0.00476	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	7.04e-05	0.00466	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	6.96e-05	0.00461	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	6.94e-05	0.0046	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	6.91e-05	0.00458	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	6.66e-05	0.00441	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	6.62e-05	0.00438	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	6.44e-05	0.00426	CbGpPWpGaD
Moxifloxacin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	6.35e-05	0.00421	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	6.29e-05	0.00417	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	6.18e-05	0.00409	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	5.77e-05	0.00382	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	5.64e-05	0.00374	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	5.39e-05	0.00357	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	5.39e-05	0.00357	CbGpPWpGaD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.37e-05	0.00356	CbGpPWpGaD
Moxifloxacin—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.37e-05	0.000321	CcSEcCtD
Moxifloxacin—Urethral disorder—Epirubicin—urinary bladder cancer	5.36e-05	0.00032	CcSEcCtD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.33e-05	0.00353	CbGpPWpGaD
Moxifloxacin—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.33e-05	0.000318	CcSEcCtD
Moxifloxacin—Epistaxis—Doxorubicin—urinary bladder cancer	5.31e-05	0.000317	CcSEcCtD
Moxifloxacin—Angiopathy—Methotrexate—urinary bladder cancer	5.3e-05	0.000316	CcSEcCtD
Moxifloxacin—Sinusitis—Doxorubicin—urinary bladder cancer	5.28e-05	0.000316	CcSEcCtD
Moxifloxacin—Immune system disorder—Methotrexate—urinary bladder cancer	5.27e-05	0.000315	CcSEcCtD
Moxifloxacin—Dizziness—Fluorouracil—urinary bladder cancer	5.27e-05	0.000315	CcSEcCtD
Moxifloxacin—Visual impairment—Epirubicin—urinary bladder cancer	5.27e-05	0.000315	CcSEcCtD
Moxifloxacin—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.26e-05	0.000314	CcSEcCtD
Moxifloxacin—Agranulocytosis—Doxorubicin—urinary bladder cancer	5.26e-05	0.000314	CcSEcCtD
Moxifloxacin—Chills—Methotrexate—urinary bladder cancer	5.24e-05	0.000313	CcSEcCtD
Moxifloxacin—Diarrhoea—Cisplatin—urinary bladder cancer	5.17e-05	0.000309	CcSEcCtD
Moxifloxacin—Erythema multiforme—Epirubicin—urinary bladder cancer	5.17e-05	0.000309	CcSEcCtD
Moxifloxacin—Vomiting—Gemcitabine—urinary bladder cancer	5.16e-05	0.000308	CcSEcCtD
Moxifloxacin—Bradycardia—Doxorubicin—urinary bladder cancer	5.15e-05	0.000307	CcSEcCtD
Moxifloxacin—Mental disorder—Methotrexate—urinary bladder cancer	5.12e-05	0.000306	CcSEcCtD
Moxifloxacin—Rash—Gemcitabine—urinary bladder cancer	5.11e-05	0.000305	CcSEcCtD
Moxifloxacin—Dermatitis—Gemcitabine—urinary bladder cancer	5.11e-05	0.000305	CcSEcCtD
Moxifloxacin—Eye disorder—Epirubicin—urinary bladder cancer	5.11e-05	0.000305	CcSEcCtD
Moxifloxacin—Hypersensitivity—Etoposide—urinary bladder cancer	5.1e-05	0.000305	CcSEcCtD
Moxifloxacin—Tinnitus—Epirubicin—urinary bladder cancer	5.09e-05	0.000304	CcSEcCtD
Moxifloxacin—Erythema—Methotrexate—urinary bladder cancer	5.08e-05	0.000304	CcSEcCtD
Moxifloxacin—Malnutrition—Methotrexate—urinary bladder cancer	5.08e-05	0.000304	CcSEcCtD
Moxifloxacin—Haemoglobin—Doxorubicin—urinary bladder cancer	5.08e-05	0.000304	CcSEcCtD
Moxifloxacin—Headache—Gemcitabine—urinary bladder cancer	5.08e-05	0.000304	CcSEcCtD
Moxifloxacin—Cardiac disorder—Epirubicin—urinary bladder cancer	5.07e-05	0.000303	CcSEcCtD
Moxifloxacin—Vomiting—Fluorouracil—urinary bladder cancer	5.07e-05	0.000303	CcSEcCtD
Moxifloxacin—Rhinitis—Doxorubicin—urinary bladder cancer	5.07e-05	0.000303	CcSEcCtD
Moxifloxacin—Hepatitis—Doxorubicin—urinary bladder cancer	5.06e-05	0.000302	CcSEcCtD
Moxifloxacin—Haemorrhage—Doxorubicin—urinary bladder cancer	5.06e-05	0.000302	CcSEcCtD
Moxifloxacin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	5.03e-05	0.000301	CcSEcCtD
Moxifloxacin—Rash—Fluorouracil—urinary bladder cancer	5.03e-05	0.0003	CcSEcCtD
Moxifloxacin—Dermatitis—Fluorouracil—urinary bladder cancer	5.02e-05	0.0003	CcSEcCtD
Moxifloxacin—Pharyngitis—Doxorubicin—urinary bladder cancer	5.02e-05	0.0003	CcSEcCtD
Moxifloxacin—Headache—Fluorouracil—urinary bladder cancer	5e-05	0.000298	CcSEcCtD
Moxifloxacin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.99e-05	0.000298	CcSEcCtD
Moxifloxacin—Oedema peripheral—Doxorubicin—urinary bladder cancer	4.98e-05	0.000298	CcSEcCtD
Moxifloxacin—Dysgeusia—Methotrexate—urinary bladder cancer	4.98e-05	0.000297	CcSEcCtD
Moxifloxacin—Asthenia—Etoposide—urinary bladder cancer	4.97e-05	0.000297	CcSEcCtD
Moxifloxacin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.97e-05	0.000297	CcSEcCtD
Moxifloxacin—Angiopathy—Epirubicin—urinary bladder cancer	4.96e-05	0.000296	CcSEcCtD
Moxifloxacin—Urethral disorder—Doxorubicin—urinary bladder cancer	4.96e-05	0.000296	CcSEcCtD
Moxifloxacin—Immune system disorder—Epirubicin—urinary bladder cancer	4.94e-05	0.000295	CcSEcCtD
Moxifloxacin—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.92e-05	0.000294	CcSEcCtD
Moxifloxacin—Back pain—Methotrexate—urinary bladder cancer	4.92e-05	0.000294	CcSEcCtD
Moxifloxacin—Chills—Epirubicin—urinary bladder cancer	4.9e-05	0.000293	CcSEcCtD
Moxifloxacin—Pruritus—Etoposide—urinary bladder cancer	4.9e-05	0.000293	CcSEcCtD
Moxifloxacin—Arrhythmia—Epirubicin—urinary bladder cancer	4.88e-05	0.000292	CcSEcCtD
Moxifloxacin—Visual impairment—Doxorubicin—urinary bladder cancer	4.87e-05	0.000291	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	4.84e-05	0.0032	CbGpPWpGaD
Moxifloxacin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	4.82e-05	0.00319	CbGpPWpGaD
Moxifloxacin—Nausea—Gemcitabine—urinary bladder cancer	4.82e-05	0.000288	CcSEcCtD
Moxifloxacin—Vomiting—Cisplatin—urinary bladder cancer	4.81e-05	0.000287	CcSEcCtD
Moxifloxacin—Vision blurred—Methotrexate—urinary bladder cancer	4.79e-05	0.000286	CcSEcCtD
Moxifloxacin—Mental disorder—Epirubicin—urinary bladder cancer	4.79e-05	0.000286	CcSEcCtD
Moxifloxacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	4.78e-05	0.000286	CcSEcCtD
Moxifloxacin—Rash—Cisplatin—urinary bladder cancer	4.77e-05	0.000285	CcSEcCtD
Moxifloxacin—Dermatitis—Cisplatin—urinary bladder cancer	4.76e-05	0.000284	CcSEcCtD
Moxifloxacin—Malnutrition—Epirubicin—urinary bladder cancer	4.76e-05	0.000284	CcSEcCtD
Moxifloxacin—Erythema—Epirubicin—urinary bladder cancer	4.76e-05	0.000284	CcSEcCtD
Moxifloxacin—Diarrhoea—Etoposide—urinary bladder cancer	4.74e-05	0.000283	CcSEcCtD
Moxifloxacin—Nausea—Fluorouracil—urinary bladder cancer	4.74e-05	0.000283	CcSEcCtD
Moxifloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.74e-05	0.00314	CbGpPWpGaD
Moxifloxacin—Eye disorder—Doxorubicin—urinary bladder cancer	4.73e-05	0.000282	CcSEcCtD
Moxifloxacin—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.72e-05	0.000282	CcSEcCtD
Moxifloxacin—Tinnitus—Doxorubicin—urinary bladder cancer	4.71e-05	0.000282	CcSEcCtD
Moxifloxacin—Anaemia—Methotrexate—urinary bladder cancer	4.7e-05	0.000281	CcSEcCtD
Moxifloxacin—Cardiac disorder—Doxorubicin—urinary bladder cancer	4.69e-05	0.00028	CcSEcCtD
Moxifloxacin—Flatulence—Epirubicin—urinary bladder cancer	4.69e-05	0.00028	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	4.69e-05	0.0031	CbGpPWpGaD
Moxifloxacin—Tension—Epirubicin—urinary bladder cancer	4.67e-05	0.000279	CcSEcCtD
Moxifloxacin—Dysgeusia—Epirubicin—urinary bladder cancer	4.66e-05	0.000278	CcSEcCtD
Moxifloxacin—Nervousness—Epirubicin—urinary bladder cancer	4.62e-05	0.000276	CcSEcCtD
Moxifloxacin—Back pain—Epirubicin—urinary bladder cancer	4.6e-05	0.000275	CcSEcCtD
Moxifloxacin—Angiopathy—Doxorubicin—urinary bladder cancer	4.59e-05	0.000274	CcSEcCtD
Moxifloxacin—Malaise—Methotrexate—urinary bladder cancer	4.58e-05	0.000274	CcSEcCtD
Moxifloxacin—Dizziness—Etoposide—urinary bladder cancer	4.58e-05	0.000274	CcSEcCtD
Moxifloxacin—Muscle spasms—Epirubicin—urinary bladder cancer	4.57e-05	0.000273	CcSEcCtD
Moxifloxacin—Immune system disorder—Doxorubicin—urinary bladder cancer	4.57e-05	0.000273	CcSEcCtD
Moxifloxacin—Vertigo—Methotrexate—urinary bladder cancer	4.57e-05	0.000273	CcSEcCtD
Moxifloxacin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.56e-05	0.000272	CcSEcCtD
Moxifloxacin—Leukopenia—Methotrexate—urinary bladder cancer	4.55e-05	0.000272	CcSEcCtD
Moxifloxacin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	4.55e-05	0.00301	CbGpPWpGaD
Moxifloxacin—Chills—Doxorubicin—urinary bladder cancer	4.54e-05	0.000271	CcSEcCtD
Moxifloxacin—Arrhythmia—Doxorubicin—urinary bladder cancer	4.52e-05	0.00027	CcSEcCtD
Moxifloxacin—Nausea—Cisplatin—urinary bladder cancer	4.49e-05	0.000268	CcSEcCtD
Moxifloxacin—Vision blurred—Epirubicin—urinary bladder cancer	4.48e-05	0.000268	CcSEcCtD
Moxifloxacin—Cough—Methotrexate—urinary bladder cancer	4.44e-05	0.000265	CcSEcCtD
Moxifloxacin—Mental disorder—Doxorubicin—urinary bladder cancer	4.43e-05	0.000265	CcSEcCtD
Moxifloxacin—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.41e-05	0.000264	CcSEcCtD
Moxifloxacin—Convulsion—Methotrexate—urinary bladder cancer	4.4e-05	0.000263	CcSEcCtD
Moxifloxacin—Vomiting—Etoposide—urinary bladder cancer	4.4e-05	0.000263	CcSEcCtD
Moxifloxacin—Malnutrition—Doxorubicin—urinary bladder cancer	4.4e-05	0.000263	CcSEcCtD
Moxifloxacin—Erythema—Doxorubicin—urinary bladder cancer	4.4e-05	0.000263	CcSEcCtD
Moxifloxacin—Anaemia—Epirubicin—urinary bladder cancer	4.4e-05	0.000263	CcSEcCtD
Moxifloxacin—Agitation—Epirubicin—urinary bladder cancer	4.37e-05	0.000261	CcSEcCtD
Moxifloxacin—Rash—Etoposide—urinary bladder cancer	4.37e-05	0.000261	CcSEcCtD
Moxifloxacin—Dermatitis—Etoposide—urinary bladder cancer	4.36e-05	0.000261	CcSEcCtD
Moxifloxacin—Headache—Etoposide—urinary bladder cancer	4.34e-05	0.000259	CcSEcCtD
Moxifloxacin—Flatulence—Doxorubicin—urinary bladder cancer	4.34e-05	0.000259	CcSEcCtD
Moxifloxacin—Myalgia—Methotrexate—urinary bladder cancer	4.33e-05	0.000259	CcSEcCtD
Moxifloxacin—Chest pain—Methotrexate—urinary bladder cancer	4.33e-05	0.000259	CcSEcCtD
Moxifloxacin—Arthralgia—Methotrexate—urinary bladder cancer	4.33e-05	0.000259	CcSEcCtD
Moxifloxacin—Tension—Doxorubicin—urinary bladder cancer	4.32e-05	0.000258	CcSEcCtD
Moxifloxacin—Dysgeusia—Doxorubicin—urinary bladder cancer	4.31e-05	0.000257	CcSEcCtD
Moxifloxacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.3e-05	0.000257	CcSEcCtD
Moxifloxacin—Malaise—Epirubicin—urinary bladder cancer	4.29e-05	0.000256	CcSEcCtD
Moxifloxacin—Discomfort—Methotrexate—urinary bladder cancer	4.28e-05	0.000255	CcSEcCtD
Moxifloxacin—Nervousness—Doxorubicin—urinary bladder cancer	4.27e-05	0.000255	CcSEcCtD
Moxifloxacin—Vertigo—Epirubicin—urinary bladder cancer	4.27e-05	0.000255	CcSEcCtD
Moxifloxacin—Syncope—Epirubicin—urinary bladder cancer	4.27e-05	0.000255	CcSEcCtD
Moxifloxacin—Leukopenia—Epirubicin—urinary bladder cancer	4.26e-05	0.000254	CcSEcCtD
Moxifloxacin—Back pain—Doxorubicin—urinary bladder cancer	4.26e-05	0.000254	CcSEcCtD
Moxifloxacin—Muscle spasms—Doxorubicin—urinary bladder cancer	4.23e-05	0.000253	CcSEcCtD
Moxifloxacin—Palpitations—Epirubicin—urinary bladder cancer	4.2e-05	0.000251	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	4.19e-05	0.00277	CbGpPWpGaD
Moxifloxacin—Confusional state—Methotrexate—urinary bladder cancer	4.18e-05	0.00025	CcSEcCtD
Moxifloxacin—Loss of consciousness—Epirubicin—urinary bladder cancer	4.18e-05	0.00025	CcSEcCtD
Moxifloxacin—Cough—Epirubicin—urinary bladder cancer	4.15e-05	0.000248	CcSEcCtD
Moxifloxacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	4.15e-05	0.000248	CcSEcCtD
Moxifloxacin—Vision blurred—Doxorubicin—urinary bladder cancer	4.15e-05	0.000248	CcSEcCtD
Moxifloxacin—Convulsion—Epirubicin—urinary bladder cancer	4.12e-05	0.000246	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	4.12e-05	0.00273	CbGpPWpGaD
Moxifloxacin—Nausea—Etoposide—urinary bladder cancer	4.11e-05	0.000246	CcSEcCtD
Moxifloxacin—Hypertension—Epirubicin—urinary bladder cancer	4.11e-05	0.000245	CcSEcCtD
Moxifloxacin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	4.08e-05	0.000244	CcSEcCtD
Moxifloxacin—Nervous system disorder—Methotrexate—urinary bladder cancer	4.07e-05	0.000243	CcSEcCtD
Moxifloxacin—Anaemia—Doxorubicin—urinary bladder cancer	4.07e-05	0.000243	CcSEcCtD
Moxifloxacin—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.06e-05	0.000243	CcSEcCtD
Moxifloxacin—Arthralgia—Epirubicin—urinary bladder cancer	4.05e-05	0.000242	CcSEcCtD
Moxifloxacin—Chest pain—Epirubicin—urinary bladder cancer	4.05e-05	0.000242	CcSEcCtD
Moxifloxacin—Myalgia—Epirubicin—urinary bladder cancer	4.05e-05	0.000242	CcSEcCtD
Moxifloxacin—Agitation—Doxorubicin—urinary bladder cancer	4.04e-05	0.000242	CcSEcCtD
Moxifloxacin—Anxiety—Epirubicin—urinary bladder cancer	4.04e-05	0.000241	CcSEcCtD
Moxifloxacin—Skin disorder—Methotrexate—urinary bladder cancer	4.03e-05	0.000241	CcSEcCtD
Moxifloxacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.02e-05	0.00024	CcSEcCtD
Moxifloxacin—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.01e-05	0.00024	CcSEcCtD
Moxifloxacin—Discomfort—Epirubicin—urinary bladder cancer	4e-05	0.000239	CcSEcCtD
Moxifloxacin—Malaise—Doxorubicin—urinary bladder cancer	3.97e-05	0.000237	CcSEcCtD
Moxifloxacin—Dry mouth—Epirubicin—urinary bladder cancer	3.96e-05	0.000237	CcSEcCtD
Moxifloxacin—Vertigo—Doxorubicin—urinary bladder cancer	3.95e-05	0.000236	CcSEcCtD
Moxifloxacin—Anorexia—Methotrexate—urinary bladder cancer	3.95e-05	0.000236	CcSEcCtD
Moxifloxacin—Syncope—Doxorubicin—urinary bladder cancer	3.95e-05	0.000236	CcSEcCtD
Moxifloxacin—Leukopenia—Doxorubicin—urinary bladder cancer	3.94e-05	0.000235	CcSEcCtD
Moxifloxacin—Confusional state—Epirubicin—urinary bladder cancer	3.91e-05	0.000234	CcSEcCtD
Moxifloxacin—Palpitations—Doxorubicin—urinary bladder cancer	3.89e-05	0.000232	CcSEcCtD
Moxifloxacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.88e-05	0.000232	CcSEcCtD
Moxifloxacin—Oedema—Epirubicin—urinary bladder cancer	3.88e-05	0.000232	CcSEcCtD
Moxifloxacin—Hypotension—Methotrexate—urinary bladder cancer	3.88e-05	0.000232	CcSEcCtD
Moxifloxacin—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.87e-05	0.000231	CcSEcCtD
Moxifloxacin—Cough—Doxorubicin—urinary bladder cancer	3.84e-05	0.000229	CcSEcCtD
Moxifloxacin—Shock—Epirubicin—urinary bladder cancer	3.82e-05	0.000228	CcSEcCtD
Moxifloxacin—Convulsion—Doxorubicin—urinary bladder cancer	3.81e-05	0.000228	CcSEcCtD
Moxifloxacin—Nervous system disorder—Epirubicin—urinary bladder cancer	3.81e-05	0.000227	CcSEcCtD
Moxifloxacin—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.8e-05	0.000227	CcSEcCtD
Moxifloxacin—Hypertension—Doxorubicin—urinary bladder cancer	3.8e-05	0.000227	CcSEcCtD
Moxifloxacin—Tachycardia—Epirubicin—urinary bladder cancer	3.79e-05	0.000226	CcSEcCtD
Moxifloxacin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.78e-05	0.000226	CcSEcCtD
Moxifloxacin—Skin disorder—Epirubicin—urinary bladder cancer	3.77e-05	0.000225	CcSEcCtD
Moxifloxacin—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.75e-05	0.000224	CcSEcCtD
Moxifloxacin—Insomnia—Methotrexate—urinary bladder cancer	3.75e-05	0.000224	CcSEcCtD
Moxifloxacin—Arthralgia—Doxorubicin—urinary bladder cancer	3.75e-05	0.000224	CcSEcCtD
Moxifloxacin—Chest pain—Doxorubicin—urinary bladder cancer	3.75e-05	0.000224	CcSEcCtD
Moxifloxacin—Myalgia—Doxorubicin—urinary bladder cancer	3.75e-05	0.000224	CcSEcCtD
Moxifloxacin—Anxiety—Doxorubicin—urinary bladder cancer	3.73e-05	0.000223	CcSEcCtD
Moxifloxacin—Paraesthesia—Methotrexate—urinary bladder cancer	3.73e-05	0.000223	CcSEcCtD
Moxifloxacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.72e-05	0.000222	CcSEcCtD
Moxifloxacin—Discomfort—Doxorubicin—urinary bladder cancer	3.7e-05	0.000221	CcSEcCtD
Moxifloxacin—Anorexia—Epirubicin—urinary bladder cancer	3.7e-05	0.000221	CcSEcCtD
Moxifloxacin—Dyspnoea—Methotrexate—urinary bladder cancer	3.7e-05	0.000221	CcSEcCtD
Moxifloxacin—Somnolence—Methotrexate—urinary bladder cancer	3.69e-05	0.00022	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	3.68e-05	0.00244	CbGpPWpGaD
Moxifloxacin—Dry mouth—Doxorubicin—urinary bladder cancer	3.66e-05	0.000219	CcSEcCtD
Moxifloxacin—Dyspepsia—Methotrexate—urinary bladder cancer	3.65e-05	0.000218	CcSEcCtD
Moxifloxacin—Hypotension—Epirubicin—urinary bladder cancer	3.63e-05	0.000217	CcSEcCtD
Moxifloxacin—Confusional state—Doxorubicin—urinary bladder cancer	3.62e-05	0.000216	CcSEcCtD
Moxifloxacin—Decreased appetite—Methotrexate—urinary bladder cancer	3.61e-05	0.000215	CcSEcCtD
Moxifloxacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.59e-05	0.000215	CcSEcCtD
Moxifloxacin—Oedema—Doxorubicin—urinary bladder cancer	3.59e-05	0.000215	CcSEcCtD
Moxifloxacin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.58e-05	0.000214	CcSEcCtD
Moxifloxacin—Fatigue—Methotrexate—urinary bladder cancer	3.58e-05	0.000214	CcSEcCtD
Moxifloxacin—Pain—Methotrexate—urinary bladder cancer	3.55e-05	0.000212	CcSEcCtD
Moxifloxacin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.54e-05	0.000211	CcSEcCtD
Moxifloxacin—Shock—Doxorubicin—urinary bladder cancer	3.53e-05	0.000211	CcSEcCtD
Moxifloxacin—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.52e-05	0.00021	CcSEcCtD
Moxifloxacin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.52e-05	0.00021	CcSEcCtD
Moxifloxacin—Insomnia—Epirubicin—urinary bladder cancer	3.51e-05	0.00021	CcSEcCtD
Moxifloxacin—Tachycardia—Doxorubicin—urinary bladder cancer	3.51e-05	0.000209	CcSEcCtD
Moxifloxacin—Skin disorder—Doxorubicin—urinary bladder cancer	3.49e-05	0.000208	CcSEcCtD
Moxifloxacin—Paraesthesia—Epirubicin—urinary bladder cancer	3.49e-05	0.000208	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	3.48e-05	0.0023	CbGpPWpGaD
Moxifloxacin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.47e-05	0.000207	CcSEcCtD
Moxifloxacin—Dyspnoea—Epirubicin—urinary bladder cancer	3.46e-05	0.000207	CcSEcCtD
Moxifloxacin—Somnolence—Epirubicin—urinary bladder cancer	3.45e-05	0.000206	CcSEcCtD
Moxifloxacin—Anorexia—Doxorubicin—urinary bladder cancer	3.42e-05	0.000205	CcSEcCtD
Moxifloxacin—Feeling abnormal—Methotrexate—urinary bladder cancer	3.42e-05	0.000204	CcSEcCtD
Moxifloxacin—Dyspepsia—Epirubicin—urinary bladder cancer	3.42e-05	0.000204	CcSEcCtD
Moxifloxacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.39e-05	0.000203	CcSEcCtD
Moxifloxacin—Decreased appetite—Epirubicin—urinary bladder cancer	3.37e-05	0.000202	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	3.37e-05	0.00223	CbGpPWpGaD
Moxifloxacin—Hypotension—Doxorubicin—urinary bladder cancer	3.36e-05	0.000201	CcSEcCtD
Moxifloxacin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.35e-05	0.0002	CcSEcCtD
Moxifloxacin—Fatigue—Epirubicin—urinary bladder cancer	3.35e-05	0.0002	CcSEcCtD
Moxifloxacin—Constipation—Epirubicin—urinary bladder cancer	3.32e-05	0.000198	CcSEcCtD
Moxifloxacin—Pain—Epirubicin—urinary bladder cancer	3.32e-05	0.000198	CcSEcCtD
Moxifloxacin—Urticaria—Methotrexate—urinary bladder cancer	3.3e-05	0.000197	CcSEcCtD
Moxifloxacin—Body temperature increased—Methotrexate—urinary bladder cancer	3.28e-05	0.000196	CcSEcCtD
Moxifloxacin—Abdominal pain—Methotrexate—urinary bladder cancer	3.28e-05	0.000196	CcSEcCtD
Moxifloxacin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.27e-05	0.000195	CcSEcCtD
Moxifloxacin—Insomnia—Doxorubicin—urinary bladder cancer	3.25e-05	0.000194	CcSEcCtD
Moxifloxacin—Paraesthesia—Doxorubicin—urinary bladder cancer	3.23e-05	0.000193	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	3.2e-05	0.00212	CbGpPWpGaD
Moxifloxacin—Dyspnoea—Doxorubicin—urinary bladder cancer	3.2e-05	0.000191	CcSEcCtD
Moxifloxacin—Feeling abnormal—Epirubicin—urinary bladder cancer	3.2e-05	0.000191	CcSEcCtD
Moxifloxacin—Somnolence—Doxorubicin—urinary bladder cancer	3.19e-05	0.000191	CcSEcCtD
Moxifloxacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.17e-05	0.00019	CcSEcCtD
Moxifloxacin—Dyspepsia—Doxorubicin—urinary bladder cancer	3.16e-05	0.000189	CcSEcCtD
Moxifloxacin—Decreased appetite—Doxorubicin—urinary bladder cancer	3.12e-05	0.000187	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	3.11e-05	0.00206	CbGpPWpGaD
Moxifloxacin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.1e-05	0.000185	CcSEcCtD
Moxifloxacin—Fatigue—Doxorubicin—urinary bladder cancer	3.1e-05	0.000185	CcSEcCtD
Moxifloxacin—Urticaria—Epirubicin—urinary bladder cancer	3.08e-05	0.000184	CcSEcCtD
Moxifloxacin—Constipation—Doxorubicin—urinary bladder cancer	3.07e-05	0.000183	CcSEcCtD
Moxifloxacin—Pain—Doxorubicin—urinary bladder cancer	3.07e-05	0.000183	CcSEcCtD
Moxifloxacin—Abdominal pain—Epirubicin—urinary bladder cancer	3.07e-05	0.000183	CcSEcCtD
Moxifloxacin—Body temperature increased—Epirubicin—urinary bladder cancer	3.07e-05	0.000183	CcSEcCtD
Moxifloxacin—Hypersensitivity—Methotrexate—urinary bladder cancer	3.06e-05	0.000183	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	3.01e-05	0.00199	CbGpPWpGaD
Moxifloxacin—Asthenia—Methotrexate—urinary bladder cancer	2.98e-05	0.000178	CcSEcCtD
Moxifloxacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.96e-05	0.000177	CcSEcCtD
Moxifloxacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.94e-05	0.000175	CcSEcCtD
Moxifloxacin—Pruritus—Methotrexate—urinary bladder cancer	2.94e-05	0.000175	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	2.87e-05	0.0019	CbGpPWpGaD
Moxifloxacin—Hypersensitivity—Epirubicin—urinary bladder cancer	2.86e-05	0.000171	CcSEcCtD
Moxifloxacin—Urticaria—Doxorubicin—urinary bladder cancer	2.85e-05	0.00017	CcSEcCtD
Moxifloxacin—Abdominal pain—Doxorubicin—urinary bladder cancer	2.84e-05	0.00017	CcSEcCtD
Moxifloxacin—Body temperature increased—Doxorubicin—urinary bladder cancer	2.84e-05	0.00017	CcSEcCtD
Moxifloxacin—Diarrhoea—Methotrexate—urinary bladder cancer	2.84e-05	0.00017	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	2.79e-05	0.00185	CbGpPWpGaD
Moxifloxacin—Asthenia—Epirubicin—urinary bladder cancer	2.79e-05	0.000166	CcSEcCtD
Moxifloxacin—Pruritus—Epirubicin—urinary bladder cancer	2.75e-05	0.000164	CcSEcCtD
Moxifloxacin—Dizziness—Methotrexate—urinary bladder cancer	2.74e-05	0.000164	CcSEcCtD
Moxifloxacin—Diarrhoea—Epirubicin—urinary bladder cancer	2.66e-05	0.000159	CcSEcCtD
Moxifloxacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.65e-05	0.000158	CcSEcCtD
Moxifloxacin—Vomiting—Methotrexate—urinary bladder cancer	2.64e-05	0.000158	CcSEcCtD
Moxifloxacin—Rash—Methotrexate—urinary bladder cancer	2.62e-05	0.000156	CcSEcCtD
Moxifloxacin—Dermatitis—Methotrexate—urinary bladder cancer	2.61e-05	0.000156	CcSEcCtD
Moxifloxacin—Headache—Methotrexate—urinary bladder cancer	2.6e-05	0.000155	CcSEcCtD
Moxifloxacin—Asthenia—Doxorubicin—urinary bladder cancer	2.58e-05	0.000154	CcSEcCtD
Moxifloxacin—Dizziness—Epirubicin—urinary bladder cancer	2.57e-05	0.000153	CcSEcCtD
Moxifloxacin—Pruritus—Doxorubicin—urinary bladder cancer	2.54e-05	0.000152	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	2.5e-05	0.00165	CbGpPWpGaD
Moxifloxacin—Vomiting—Epirubicin—urinary bladder cancer	2.47e-05	0.000147	CcSEcCtD
Moxifloxacin—Nausea—Methotrexate—urinary bladder cancer	2.46e-05	0.000147	CcSEcCtD
Moxifloxacin—Diarrhoea—Doxorubicin—urinary bladder cancer	2.46e-05	0.000147	CcSEcCtD
Moxifloxacin—Rash—Epirubicin—urinary bladder cancer	2.45e-05	0.000146	CcSEcCtD
Moxifloxacin—Dermatitis—Epirubicin—urinary bladder cancer	2.45e-05	0.000146	CcSEcCtD
Moxifloxacin—Headache—Epirubicin—urinary bladder cancer	2.43e-05	0.000145	CcSEcCtD
Moxifloxacin—Dizziness—Doxorubicin—urinary bladder cancer	2.38e-05	0.000142	CcSEcCtD
Moxifloxacin—Nausea—Epirubicin—urinary bladder cancer	2.31e-05	0.000138	CcSEcCtD
Moxifloxacin—Vomiting—Doxorubicin—urinary bladder cancer	2.28e-05	0.000136	CcSEcCtD
Moxifloxacin—Rash—Doxorubicin—urinary bladder cancer	2.26e-05	0.000135	CcSEcCtD
Moxifloxacin—Dermatitis—Doxorubicin—urinary bladder cancer	2.26e-05	0.000135	CcSEcCtD
Moxifloxacin—Headache—Doxorubicin—urinary bladder cancer	2.25e-05	0.000134	CcSEcCtD
Moxifloxacin—Nausea—Doxorubicin—urinary bladder cancer	2.13e-05	0.000127	CcSEcCtD
Moxifloxacin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	2.05e-05	0.00136	CbGpPWpGaD
